Epidemiology of Prostate Cancer in the Republic of Kazakhstan.

Kazakhstan Morbidity Mortality Prostate cancer Screening program

Journal

Iranian journal of public health
ISSN: 2251-6085
Titre abrégé: Iran J Public Health
Pays: Iran
ID NLM: 7505531

Informations de publication

Date de publication:
Dec 2019
Historique:
entrez: 30 1 2020
pubmed: 30 1 2020
medline: 30 1 2020
Statut: ppublish

Résumé

The incidence and mortality from prostate cancer in most native Asian populations remain low although a gradual increase is observed over the last years. The statistical analysis of official data on prostate cancer mortality and morbidity was performed for the whole country and for Pavlodar Region. The increase in the incidence of prostate cancer among the population of Kazakhstan is observed, which may be attributed to the introduction of screening program based on serum PSA. Still, the crude incidence rates in Kazakhstan are below world indices. Over the last few years, the decreasing prostate cancer mortality is observed that might be influenced by early diagnosis. The age-standardized incidence rates show that the majority of prostate cancer cases occur in advanced ages (70 years and older). More research is needed to determine the risk factors for prostate cancer, as well as ethnic and geographical trends for the population of Kazakhstan.

Sections du résumé

BACKGROUND BACKGROUND
The incidence and mortality from prostate cancer in most native Asian populations remain low although a gradual increase is observed over the last years.
METHODS METHODS
The statistical analysis of official data on prostate cancer mortality and morbidity was performed for the whole country and for Pavlodar Region.
RESULTS RESULTS
The increase in the incidence of prostate cancer among the population of Kazakhstan is observed, which may be attributed to the introduction of screening program based on serum PSA. Still, the crude incidence rates in Kazakhstan are below world indices. Over the last few years, the decreasing prostate cancer mortality is observed that might be influenced by early diagnosis. The age-standardized incidence rates show that the majority of prostate cancer cases occur in advanced ages (70 years and older).
CONCLUSION CONCLUSIONS
More research is needed to determine the risk factors for prostate cancer, as well as ethnic and geographical trends for the population of Kazakhstan.

Identifiants

pubmed: 31993390
pmc: PMC6974858

Types de publication

Journal Article

Langues

eng

Pagination

2216-2223

Informations de copyright

Copyright© Iranian Public Health Association & Tehran University of Medical Sciences.

Déclaration de conflit d'intérêts

Conflict of interests The authors declare that there is no conflict of interests.

Références

Public Health. 2015 Jul;129(7):1010-3
pubmed: 25986952
Int J Environ Res Public Health. 2018 Feb 13;15(2):
pubmed: 29438330
J Dev Orig Health Dis. 2010 Jun;1(3):192-202
pubmed: 24286002
J Environ Radioact. 2018 Dec;195:33-39
pubmed: 30241015
Nat Rev Cancer. 2012 Sep;12(9):648-53
pubmed: 22854838
BMJ. 2010 Sep 14;341:c4543
pubmed: 20843937
Georgian Med News. 2017 Nov;(272):17-22
pubmed: 29227252
Eur Urol. 2012 Jun;61(6):1079-92
pubmed: 22424666
Environ Res. 2018 Nov;167:129-135
pubmed: 30014894
Vopr Onkol. 2014;60(4):457-63
pubmed: 25552064
Ann Intern Med. 2012 Jul 17;157(2):120-34
pubmed: 22801674
Vopr Onkol. 2009;55(5):555-61
pubmed: 20020649
Nat Rev Urol. 2014 Apr;11(4):197-212
pubmed: 24595118
Int J Cancer. 2013 Mar 1;132(5):1133-45
pubmed: 22752881
Vestn Ross Akad Med Nauk. 2007;(11):45-9
pubmed: 18080527
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Cancer Causes Control. 2007 Apr;18(3):279-85
pubmed: 17206534
Iran J Public Health. 2016 Jun;45(6):729-38
pubmed: 27648415
Int J Occup Environ Health. 2015 Jul-Sep;21(3):251-7
pubmed: 25785490
Prostate. 2004 Jun 15;60(1):46-52
pubmed: 15129428
Adv Gerontol. 2017;30(6):818-825
pubmed: 29608822
Int J Cancer. 2010 Dec 15;127(12):2918-27
pubmed: 21351270
Iran J Public Health. 2017 Jul;46(7):917-922
pubmed: 28845402

Auteurs

Dariga Smailova (D)

Department of Innovations in Science, Semey Medical University, Semey, Republic of Kazakhstan.

Erlan Ospanov (E)

Department of Neurology, Ophthalmology, and ENT, Semey Medical University, Semey, Republic of Kazakhstan.

Meruert Gazaliyeva (M)

Department of Clinical Immunology, Allergology, and Microbiology, Karaganda Medical University, Karaganda, Republic of Kazakhstan.

Dilyara Kaidarova (D)

Kazakh Institute of Oncology and Radiology, Almaty, Republic of Kazakhstan.

Oxana Shatkovskaya (O)

Kazakh Institute of Oncology and Radiology, Almaty, Republic of Kazakhstan.

Zhanar Zamanbekova (Z)

Department of Endocrinology, Semey Medical University, Semey, Republic of Kazakhstan.

Kuralay Amrenova (K)

Department of Personalized Medicine, Semey Medical University, Semey, Republic of Kazakhstan.

Tatyana Belikhina (T)

Semey Regional Oncology Center, Semey, Republic of Kazakhstan.

Tasbolat Adylkhanov (T)

Department of Oncology, Semey Medical University, Semey, Republic of Kazakhstan.

Ardak Omarbekov (A)

Department of Surgical Diseases ?2, Astana Medical University, Astana, Republic of Kazakhstan.

Marzhan Dauletyarova (M)

Research Office, Astana Medical University, Astana, Republic of Kazakhstan.

Lyudmila Pivina (L)

Department of Emergency Medicine, Semey Medical University, Semey, Republic of Kazakhstan.

Yuliya Semenova (Y)

Department of Neurology, Ophthalmology, and ENT, Semey Medical University, Semey, Republic of Kazakhstan.

Classifications MeSH